No they would be obliged to include entire dataset. This is...

No they would be obliged to include entire dataset. This is generally presented in an intention-to-treat analysis. I think the problem is that they don’t really know what went wrong in the vehicle arm in the US. If there was an obvious error that they knew about that would invalidate the entire study and all they could do at that point is to repeat the study which I guess is what we are doing in terms of going to phase 3. As I think others have pointed out just looking at the Australian data in isolation is what we call a post-hoc analysis and we are limited by convention of what we can draw from this anyway good luck to all long-term holders ,at least we very confident the drug works and are moving on to phase 3.